Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough.

NCT05888350 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 502

Last updated 2026-02-18

No results posted yet for this study

Summary

To investigate the value of blood eosinophils, FeNO and total IgE in predicting the response to inhaled corticosteroid in patients with chronic cough.

Conditions

Interventions

DRUG

Beclometasone Dipropionate and Formoterol Inhalation Aerosol

Inhaled Foster (Beclometasone Dipropionate and Formoterol Inhalation Aerosol) , 1puff, BID, 4weeks

DRUG

Placebo

Inhaled Placebo, 1puff, BID, 4weeks

Sponsors & Collaborators

  • Huizhou Third People's Hospital

    collaborator UNKNOWN
  • Guangdong Provincial Hospital of Traditional Chinese Medicine

    collaborator OTHER
  • Nanfang Hospital, Southern Medical University

    collaborator OTHER
  • Shenzhen People's Hospital

    collaborator OTHER
  • SSL Central Hospital of Dongguan City

    collaborator UNKNOWN
  • China-Japan Friendship Hospital

    collaborator OTHER
  • Beijing Chao Yang Hospital

    collaborator OTHER
  • Zunyi Medical College

    collaborator OTHER
  • Henan Provincial People's Hospital

    collaborator OTHER
  • The First Affiliated Hospital of Henan University of Traditional Chinese Medicine

    collaborator OTHER
  • Second Hospital of Jilin University

    collaborator OTHER
  • Inner Mongolia People's Hospital

    collaborator OTHER
  • The First Affiliated Hospital of Shanxi Medical University

    collaborator OTHER
  • Ruijin Hospital

    collaborator OTHER
  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    collaborator OTHER
  • Tongji Hospital

    collaborator OTHER
  • First Hospital of China Medical University

    collaborator OTHER
  • Chongqing Songshan Hospital

    collaborator UNKNOWN
  • The First People's Hospital of Yunnan

    collaborator OTHER
  • The First Affiliated Hospital of Guangzhou Medical University

    lead OTHER

Principal Investigators

  • Kefang Lai, phD · The First Affiliated Hospital of Guangzhou Medical University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2025-04-30
Completion
2025-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05888350 on ClinicalTrials.gov